Reactivation of solar erythema by methotrexate is an uncommon but well-documented phenomenon. Enhancement of previous sunburn inflammation may occur if methotrexate is administered during the subsiding phase of ultraviolet light-induced erythema (between one and three days). This does not occur when it is administered either simultaneously or more than five days after ultraviolet light exposure. Methotrexate is not an infrequently used drug in chemotherapy protocols. The following, however, is an uncommon side effect of this medication in a 13 year old boy.
|Number of pages||2|
|State||Published - 1986|